Sign in
Enrolling by invitationNo phase

Studies whether migraine medicines affect bladder symptoms and pelvic pain

Observes bladder symptoms and pain in adults with migraine receiving migraine medicines.

Key facts

Who runs it
The Cleveland Clinic
Where
Cleveland, United StatesSee the site
Trial code
Registry title
Migraine Medication Effects on Urinary Symptoms
Status
Enrolling by invitation
People taking part
200 people, planned
Started
5 Apr 2024
Expected to end
Dec 2027
Type of study
Observational, 2 groups
Treatments tested
  • Ubrogepant
  • Rimegepant
  • Atogepant
  • Eptinezumab
  • Fremanezumab
  • Galcanezumab
  • Erenumab
  • Botulinum toxin A
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women over 18 with hard-to-treat migraine who plan to start a CGRP-blocking drug or BoNTA head injections, and who also have bladder symptoms.

Age
Over 18 years
Sex
Women only
Disease stage
Refractory migraine (hard to treat), with planned treatment by a CGRP inhibitor or BoNTA extracranial muscle injections.
Earlier treatment
No CGRP treatment in the last 12 months. No BoNTA to the head or bladder in the last 6 months. No bladder BoNTA in the last 12 months.

Main reasons for not taking part

  • Under 18 years
  • CGRP treatment in the last 12 months
  • BoNTA (head or bladder) in the last 6 months
  • Cannot give informed consent or answer the questionnaire
  • Cannot urinate (for example after bladder removal, indwelling catheter, self-catheterization, ESRD with anuria)

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Female Patients > 18 years
  • Refractory migraine, planned treatment with either:
  • CGRP inhibitors, including:; CGRP small molecule receptor antagonists ("gepants"): Ubrogepant, Rimegepant, Atogepant; CGRP monoclonal antibodies: Eptinezumab, Fremanezumab, Galcanezumab; CGRP receptor monoclonal antibodies: Erenumab
  • BoNTA extracranial muscle injections
  • Any of the following symptoms during the last month:; Urinating too often (frequency); Having a sudden urge to urinate that's difficult to hold back (urgency); Having a sudden urge to urinate and urine leaking before you make it to the toilet (urge incontinence)

Who cannot take part

  • Prior bladder BoNTA in last 12 months
  • Age < 18 years
  • CGRP treatment within the last 12 months or BoNTA (head / bladder) last 6 months
  • Patient (or medical decision-maker) unable to provide informed consent or unable to answer questionnaire
  • Unable to urinate, eg: post cystectomy, indwelling catheter, on intermittent self catheterization, ESRD w/ anuria

Where in United States

  • Cleveland Clinic - Main CampusCleveland, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.

The 2 groups in the trial

  • CGRP inhibitor

    * Ubrogepant (Ubrelvy™) * Rimegepant (Nurtec®) * Atogepant (Qulipta™) * Eptinezumab (Vyepti®) * Fremanezumab (Ajovy®) * Galcanezumab (Emgality®) * Erenumab (Aimovig®) dosage and duration according to provider's clinical decision.

    Treatment: Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, and Erenumab

  • BoNTA extracranial muscle injections

    Botolinum toxin A (Botox) Injection into extracranial muscles to treat migraine. Dosage and duration according to provider's clinical decision

    Treatment: Botulinum toxin A

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Migraine Medication Effects on Urinary Symptoms
Plain-language title
Studies whether migraine medicines affect bladder symptoms and pelvic painGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 October 2026